BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 38484745)

  • 1. Elimination of transmission of onchocerciasis (river blindness) with long-term ivermectin mass drug administration with or without vector control in sub-Saharan Africa: a systematic review and meta-analysis.
    Mutono N; Basáñez MG; James A; Stolk WA; Makori A; Kimani TN; Hollingsworth TD; Vasconcelos A; Dixon MA; de Vlas SJ; Thumbi SM
    Lancet Glob Health; 2024 May; 12(5):e771-e782. PubMed ID: 38484745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elimination of onchocerciasis from Colombia: first proof of concept of river blindness elimination in the world.
    Nicholls RS; Duque S; Olaya LA; López MC; Sánchez SB; Morales AL; Palma GI
    Parasit Vectors; 2018 Apr; 11(1):237. PubMed ID: 29642939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modelling the impact of ivermectin on River Blindness and its burden of morbidity and mortality in African Savannah: EpiOncho projections.
    Turner HC; Walker M; Churcher TS; Basáñez MG
    Parasit Vectors; 2014 May; 7():241. PubMed ID: 24886747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Doxycycline plus ivermectin versus ivermectin alone for treatment of patients with onchocerciasis.
    Abegunde AT; Ahuja RM; Okafor NJ
    Cochrane Database Syst Rev; 2016 Jan; 2016(1):CD011146. PubMed ID: 26771164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Onchocerca volvulus infection and serological prevalence, ocular onchocerciasis and parasite transmission in northern and central Togo after decades of Simulium damnosum s.l. vector control and mass drug administration of ivermectin.
    Komlan K; Vossberg PS; Gantin RG; Solim T; Korbmacher F; Banla M; Padjoudoum K; Karabou P; Köhler C; Soboslay PT
    PLoS Negl Trop Dis; 2018 Mar; 12(3):e0006312. PubMed ID: 29494606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modelling the elimination of river blindness using long-term epidemiological and programmatic data from Mali and Senegal.
    Walker M; Stolk WA; Dixon MA; Bottomley C; Diawara L; Traoré MO; de Vlas SJ; Basáñez MG
    Epidemics; 2017 Mar; 18():4-15. PubMed ID: 28279455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identifying co-endemic areas for major filarial infections in sub-Saharan Africa: seeking synergies and preventing severe adverse events during mass drug administration campaigns.
    Cano J; Basáñez MG; O'Hanlon SJ; Tekle AH; Wanji S; Zouré HG; Rebollo MP; Pullan RL
    Parasit Vectors; 2018 Jan; 11(1):70. PubMed ID: 29382363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of epilepsy in the onchocerciasis endemic middle belt of Ghana after 27 years of mass drug administration with ivermectin.
    Otabil KB; Ankrah B; Bart-Plange EJ; Donkoh ES; Avarikame FA; Ofori-Appiah FO; Babae TN; Kudzordzi PC; Darko VA; Ameyaw J; Bamfo JG; Sakibu RA; Antwi-Berko D; Fodjo JNS; Basáñez MG; Schallig HDFH; Colebunders R
    Infect Dis Poverty; 2023 Aug; 12(1):75. PubMed ID: 37587500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Onchocerciasis-associated epilepsy in Maridi, South Sudan: Modelling and exploring the impact of control measures against river blindness.
    Bhattacharyya S; Vinkeles Melchers NVS; Siewe Fodjo JN; Vutha A; Coffeng LE; Logora MY; Colebunders R; Stolk WA
    PLoS Negl Trop Dis; 2023 May; 17(5):e0011320. PubMed ID: 37235598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How Can Onchocerciasis Elimination in Africa Be Accelerated? Modeling the Impact of Increased Ivermectin Treatment Frequency and Complementary Vector Control.
    Verver S; Walker M; Kim YE; Fobi G; Tekle AH; Zouré HGM; Wanji S; Boakye DA; Kuesel AC; de Vlas SJ; Boussinesq M; Basáñez MG; Stolk WA
    Clin Infect Dis; 2018 Jun; 66(suppl_4):S267-S274. PubMed ID: 29860291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vector control and entomological capacity for onchocerciasis elimination.
    Tirados I; Thomsen E; Worrall E; Koala L; Melachio TT; Basáñez MG
    Trends Parasitol; 2022 Jul; 38(7):591-604. PubMed ID: 35379556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Financial and Economic Costs of the Elimination and Eradication of Onchocerciasis (River Blindness) in Africa.
    Kim YE; Sicuri E; Tediosi F
    PLoS Negl Trop Dis; 2015; 9(9):e0004056. PubMed ID: 26360917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Control, elimination, and eradication of river blindness: scenarios, timelines, and ivermectin treatment needs in Africa.
    Kim YE; Remme JH; Steinmann P; Stolk WA; Roungou JB; Tediosi F
    PLoS Negl Trop Dis; 2015 Apr; 9(4):e0003664. PubMed ID: 25860569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Feasibility of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: first evidence from studies in Mali and Senegal.
    Diawara L; Traoré MO; Badji A; Bissan Y; Doumbia K; Goita SF; Konaté L; Mounkoro K; Sarr MD; Seck AF; Toé L; Tourée S; Remme JH
    PLoS Negl Trop Dis; 2009 Jul; 3(7):e497. PubMed ID: 19621091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can mass drug administration of moxidectin accelerate onchocerciasis elimination in Africa?
    Kura K; Milton P; Hamley JID; Walker M; Bakajika DK; Kanza EM; Opoku NO; Howard H; Nigo MM; Asare S; Olipoh G; Attah SK; Mambandu GL; Kennedy KK; Kataliko K; Mumbere M; Halleux CM; Hopkins A; Kuesel AC; Kinrade S; Basáñez MG
    Philos Trans R Soc Lond B Biol Sci; 2023 Oct; 378(1887):20220277. PubMed ID: 37598705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ivermectin for onchocercal eye disease (river blindness).
    Ejere HO; Schwartz E; Wormald R; Evans JR
    Cochrane Database Syst Rev; 2012 Aug; 2012(8):CD002219. PubMed ID: 22895928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reaching the last mile: main challenges relating to and recommendations to accelerate onchocerciasis elimination in Africa.
    Gebrezgabiher G; Mekonnen Z; Yewhalaw D; Hailu A
    Infect Dis Poverty; 2019 Jul; 8(1):60. PubMed ID: 31269966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progress towards elimination of onchocerciasis transmission in Mali: A "pre-stop MDA" survey in 18 transmission zones.
    Dolo H; Coulibaly ME; Sow M; Coulibaly YI; Doumbia M; Sangare M; Sanogo A; Dembele B; Guindo B; Coulibaly M; Keita M; Soumaoro L; Diarra D; Dicko B; Hamill L; Doumbia S; Sangho H; Sangare Y; Zhang Y; Tallant J; Yaro AS; Mackenzie C; Nutman TB; Boakye D
    PLoS Negl Trop Dis; 2023 Nov; 17(11):e0011632. PubMed ID: 37967137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reaching the london declaration on neglected tropical diseases goals for onchocerciasis: an economic evaluation of increasing the frequency of ivermectin treatment in Africa.
    Turner HC; Walker M; Churcher TS; Osei-Atweneboana MY; Biritwum NK; Hopkins A; Prichard RK; Basáñez MG
    Clin Infect Dis; 2014 Oct; 59(7):923-32. PubMed ID: 24944228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.